DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
157	スタージ・ウェーバー症候群	0
227	オスラー病	2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-000385-55-FR (EUCTR)	12/05/2015	29/03/2017	Essai d’efficacité du timolol en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler.	TEMPO : Efficacité du TIMOLOL en administration nasale pour le traitement des épistaxis dans la maladie de Rendu-Osler.Essai randomisé en double insu contre placebo - TEMPO	Rendu-Osler disease MedDRA version: 19.1;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Timolol Alcon 0.5% collyre Other descriptive name: TIMOLOL MALEATE	Hospices Civils de Lyon	NULL	Not Recruiting			Female: yes Male: yes	58	Phase 2	France
2	NCT01752049 (ClinicalTrials.gov)	May 2013	14/12/2012	Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept	Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept	Hereditary Hemorrhagic Telangiectasia	Drug: Topical timolol maleate;Drug: placebo saline drops	St. Michael's Hospital, Toronto	University of California, San Francisco;The Hospital for Sick Children;University of Toronto;Sunnybrook Health Sciences Centre;Ryerson University;National Institute of Neurological Disorders and Stroke (NINDS)	Completed	18 Years	N/A	All	5	N/A	Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2015-000385-55-FR
(EUCTR)

12/05/2015

29/03/2017

Essai d’efficacité du timolol en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler.

TEMPO : Efficacité du TIMOLOL en administration nasale pour le traitement des épistaxis dans la maladie de Rendu-Osler.Essai randomisé en double insu contre placebo - TEMPO

Rendu-Osler disease
MedDRA version: 19.1;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

Trade Name: Timolol Alcon 0.5% collyre
Other descriptive name: TIMOLOL MALEATE

Hospices Civils de Lyon

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

France

NCT01752049
(ClinicalTrials.gov)

May 2013

14/12/2012

Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept

Hereditary Hemorrhagic Telangiectasia

Drug: Topical timolol maleate;Drug: placebo saline drops

St. Michael's Hospital, Toronto

University of California, San Francisco;The Hospital for Sick Children;University of Toronto;Sunnybrook Health Sciences Centre;Ryerson University;National Institute of Neurological Disorders and Stroke (NINDS)

Completed

18 Years

N/A

All

N/A

Canada